Potential antitumor agents. 19. Multiply substituted 4'-(9-acridinylamino)methanesulfonanilides.
A series of 42 multiply substituted 4'-(9-acridinylamino)methanesulfonanilides has been prepared and evaluated in the L1210 system. In addition to biologic activity changes resulting from altered agent lipophilic-hydrophilic balance variants containing both acridine 4-CH3 and 3-NH2, NHCOCH3 or NO2 substituents have reduced activity. Variants 3,6-disubstituted, using functions of differing electronic character, have depressed activity, suggesting that there is limited site bulk tolerance. Asymmetric 3,5-disubstitution should then be the preferred pattern; the 3-ND-5CH-3'-OCH variant is the most dose potent (optimum dose qd 1-5, 1.25 mg/kg/day) of the high activity agents of this series so far prepared.
D000166:Acridines / Q000138:chemical synthesis* / Q000627:therapeutic use; D000585:Aminacrine / Q000031:analogs & derivatives; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D008809:Mice, Inbred C3H; D008811:Mice, Inbred DBA; D013329:Structure-Activity Relationship
D000166:Acridines; D000970:Antineoplastic Agents; D000585:Aminacrine; C013389:4'-(9-acridinylamino)methanesulfonanilide